Canadian cancer therapy developer Zymeworks said it has adopted a “poison pill” to thwart a hostile takeover from All Blue Capital, a month after rejecting the firm’s $773 million bid on valuation grounds, Reuters reported.
Zymeworks adopts poison pill to stop All Blue takeover: Reuters
Zymeworks said the shareholder rights plan would stop investors from amassing more than 10 percent of its share.
